Search PubMed⌕ Search

PubMed · 9805957

[Homeopathy].

Abstract

The European Union and the European Council are interested in the phenomenon "Homoeopathy". At the initiative of a member of the European Parliament, Mr. Paul LANNOYE, the European Commission created a study group with the aim to answer the question: "Is Homoeopathy researchable?" After 18 month, the group, including conventional pharmacologists and researchers using daily homoeopathy, answered affirmatively to the question. On the other side, the European Council asked the European Commission to start the COST Action B4 (1993 à 1998) with the aim to analyse unconventional medicine in Europe. The experts' group from 14 different countries produced a report on the legal situation, the sociologic and scientific aspects of these practices. Homoeopathy in Europe was deeply scrutinized during this action. The general quality of the clinical publications is acceptable and we could conclude that a specific remedy action, over the placebo effect, can be scientifically expected. The total number of publications is still too low to authorize conclusions about efficacy in one particular diagnosis. About basic research more publications are available and positive results are regular. One third of the publications were published in peer reviewed international journals. Today a sound scientific hypothesis can be drawn up about working mecanisms of homoeopathic dilutions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Van Wassenhoven. 1998. [Homeopathy].. https://pubmed.ncbi.nlm.nih.gov/9805957/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Recurrence risk to offspring in extended multiplex schizophrenia pedigrees from a Pacific Island isolate.

Genetic transmission plays a major role in the pathogenesis of schizophrenia. Family, twin, and adoption studies have consistently shown that risks in relatives are many times greater than the general population risk of approximately 1%. McGue, Gottesman, and Rao (1983; Am J Hum Genet 35:1161-1178) calculated risk estimates of 12.8% for offspring and 3.5% for nieces/nephews of schizophrenia patients based on a large data set of Western European families. The present study evaluated corresponding risk levels in Palau, an isolated population in Micronesia where the prevalence of narrowly (broadly) defined schizophrenia is 1.99% (2.67%) and cases cluster in extended pedigrees, 20 of which contain 80% of affected individuals. We hypothesized that offspring in these extended families would have a higher risk for schizophrenia than offspring in smaller schizophrenia pedigrees from more genetically heterogeneous populations. RDC diagnostic data based on complete ascertainment of cases and their families covering the past two generations were used to quantify empirical recurrence risks in the offspring and nieces/nephews of Palauan schizophrenia patients. Risks to 1st- and 2nd-degree offspring were approximately double the rates found in the smaller Western European families: 23.4% in the offspring of an affected parent, 6.4% in offspring with one affected aunt/uncle, and 15.0% in offspring with two or more affected aunts/uncles. Recurrence rates in offspring of an affected parent were 1.6 times higher in males (27.9%) than in females (17.7%). The high risk levels we found in Palauan offspring reflect the elevated population prevalence, strong familial aggregation, and multi-lineal transmission pattern of schizophrenia in Palau.

Europe↗